AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

AzurRx BioPharma, Inc.

Downstate Biotechnology Incubator
Suite 304 760 Parkside Avenue
Brooklyn, NY 11226
United States
646-699-7855
http://www.azurrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. Johan M. SpoorPres, CEO & Director637.5kN/A1972
Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBACFO & Director379.17kN/A1964
Dr. Mathieu Schué Ph.D.Head of LaboratoryN/AN/AN/A
Dr. James E. PenningtonChief Medical OfficerN/AN/A1943
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Corporate Governance

AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.